

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

FOSUN PHARMA

复星医药

上海復星醫藥（集團）股份有限公司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02196)

ANNOUNCEMENT

**RESULTS OF THE PUBLIC ISSUANCE OF CORPORATE BONDS
(FIRST TRANCHE) IN 2018**

This announcement is made by the Company pursuant to Rule 13.09(2)(a) of the Listing Rules and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The Board announces that the issuance of the Current Tranche of Corporate Bonds has been completed on 15 August 2018 in the total amount of RMB1.3 billion with the final coupon rate at 5.10%.

This announcement is made by Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the “**Company**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

References are made to the announcements of the Company dated 31 March 2017 and 9 February 2018, the overseas regulatory announcements dated 31 March 2017, 18 April 2017, 9 February 2018, 9 August 2018 and 13 August 2018 (the “**Announcements**”), the circular dated 11 May 2017 (the “**Circular**”) and the poll results announcement dated 29 June 2017 in relation to, among other things, the proposed issue of Corporate Bonds in the PRC. Unless otherwise specified, capitalized terms used herein shall have the same meaning ascribed to them in the Circular and Announcements.

The approval on the public issuance of the Corporate Bonds to the qualified investors (Zheng Jian Xu Ke [2018] No. 265) was issued by CSRC on 5 February 2018, pursuant to which the public issuance of the Corporate Bonds not exceeding RMB 5 billion to qualified investors by the Company was approved. According to the “Announcement on the Public Issuance of Corporate Bonds (First Tranche) to Qualified Investors in 2018 by Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*”, the public issuance of the first tranche of Corporate Bonds to qualified investors in 2018 by the Company has an issuance size of not exceeding RMB 1.5 billion (the “**Current Tranche of the Corporate Bonds**”), with the results as follows:

The term of the Current Tranche of the Corporate Bonds issued is 5 years, and the Company shall be entitled to adjust upwards the coupon rate and the investors shall be entitled to sell back the Corporate Bonds at the end of the third year during the term of the Current Tranche of the Corporate Bonds.

The Current Tranche of the Corporate Bonds was issued by issuance method of offline issue to the qualified investors carried out based on placing through book building. The issuance of the Current Tranche of the Corporate Bonds was completed on 15 August 2018 in the total principal amount of RMB1.3 billion with the final coupon rate at 5.10%.

By order of the Board
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*
Chen Qiyu
Chairman

Shanghai, the People’s Republic of China
16 August 2018

As at the date of this announcement, the executive directors of the Company are Mr. Chen Qiyu, Mr. Yao Fang and Mr. Wu Yifang; the non-executive directors of the Company are Mr. Wang Qunbin, Mr. Wang Can, Ms. Mu Haining and Mr. Zhang Xueqing; and the independent non-executive directors of the Company are Mr. Cao Huimin, Mr. Jiang Xian, Dr. Wong Tin Yau Kelvin and Mr. Wai Shiu Kwan Danny.

* *for identification purposes only*